The co-packaged medication is not recommended during pregnancy and in women who can become pregnant but who are not using contraception. Breastfeeding should be interrupted during treatment. These recommendations are because laboratory studies in animals suggest that high doses of the co-packaged medication may affect the growth of the fetus. There are no human data on the use of<unk>  during pregnancy related to the risk of birth defects, spontaneous abortions (miscarriage), or adverse outcomes. There are also no human data on the presence of<unk>  in human milk, its effects on milk production or the infant. In pregnant rabbits, a reduction in fetal body weight was observed with systemic exposure 10 times higher than the authorized human dose of the co-packaged medication. A temporary reduction in body weight was observed in the offspring of nursing rats. Adverse drug reactions Co-administration with certain drugs may have serious effects and may sometimes be fatal. The drug is contraindicated in those with hypersensitivity to the two main components, with severely reduced kidney or liver function, co-administered with certain drugs, such as those dependent on CYP3A for removal for which a raised concentration results in serious reactions, or those with potent CYP3A inducers for which reduced blood concentration of the two main components may result in loss of effect against the virus and possible resistance, among others. Co-administration also affects the concentration of several drugs, sometimes requiring changing the dose or careful monitoring. Many of these drugs are widely prescribed to people at high risk from COVID-19.
Nirmatrelvir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Darunavir/cobicistat
Cabotegravir/rilpivirine
Ombitasvir/paritaprevir/ritonavir
Abacavir/lamivudine
Dolutegravir/rilpivirine